Other
GBM
0
Pipeline Programs↗
5
Active Trials↗
3
Companies Involved↗
GBM is an early-stage landscape with 0 programs across 3 companies. The most active players are Northwest Biotherapeutics, AbbVie, Hansa Biopharma AB.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
12
clinical trials
Terminated3 · 25%
Recruiting2 · 17%
Available2 · 17%
Active, not recruiting2 · 17%
Completed1 · 8%
Not yet recruiting1 · 8%
Other1 · 8%
Clinical Trials
Trial Activity
12 trials
Lerapolturev (PVSRIPO) in GBM
Recruiting·—·Phase 2·NCT06177964·92 enrolled
D2C7-IT + 2141-V11 Combination Post-resection in rGBM
Recruiting·—·Phase 1·NCT06455605·46 enrolled
Niraparib/TTFields in GBM
Active, not recruiting·—·Phase 2·NCT04221503·30 enrolled
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Active, not recruiting·—·Phase 2·NCT03688178·43 enrolled
Correlative Analysis Between Magnetic Resonance Spectroscopy (MRS) and Essential Clinicobiological Data in Glioblatoma Multiforme (GBM)
Not yet recruiting·—·N/A·NCT07211841·30 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)